Plasma Levels of Big Endothelin-1 Are Associated with Renal Insufficiency and In-Hospital Mortality of Immune Thrombotic Thrombocytopenic Purpura
Thieme. All rights reserved..
Immune thrombotic thrombocytopenic purpura (iTTP) is caused by severe deficiency of plasma ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) activity. Despite advances in early diagnosis and management, the mortality rate of acute iTTP remains high in a large part of world where access to some of the most novel therapies is limited. To determine the role of plasma big endothelin-1 (bigET-1) or its bioactive product ET-1 as a biomarker and/or a pathogenic factor in acute iTTP, plasma levels of bigET-1 were determined using an immunoassay in patients with iTTP on admission and during remission, as well as in healthy controls; moreover, the biological effect of ET-1 in thrombus formation was determined by a microfluidic assay. We show that plasma levels of bigET-1 were dramatically increased in patients with acute iTTP on admission, which was significantly decreased during clinical response/remission; elevated admission levels of plasma bigET-1 were associated with low estimated glomerular filtration rate, the need for intensive care unit admission or intubation, and in-hospital mortality. Moreover, an addition of a bioactive product ET-1 to cultured endothelial cells in a microfluidic channel significantly accelerated the rate of thrombus formation under arterial flow. Our results demonstrate for the first time a potential role of measuring plasma bigET-1 in patients with acute iTTP in assessing the disease severity and risk of in-hospital mortality, which may help stratify patients for a more aggressive monitoring and therapeutic strategy; also, the bioactive ET-1, derived from bigET-1, may result in acute renal injury in TTP patient, likely through its vasoconstriction and prothrombotic properties.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:122 |
---|---|
Enthalten in: |
Thrombosis and haemostasis - 122(2022), 3 vom: 25. März, Seite 344-352 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Lu, Ruinan [VerfasserIn] |
---|
Links: |
---|
Themen: |
ADAMTS13 Protein |
---|
Anmerkungen: |
Date Completed 22.03.2022 Date Revised 02.03.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1055/a-1508-8347 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM325362475 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM325362475 | ||
003 | DE-627 | ||
005 | 20231225192259.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1055/a-1508-8347 |2 doi | |
028 | 5 | 2 | |a pubmed24n1084.xml |
035 | |a (DE-627)NLM325362475 | ||
035 | |a (NLM)33984867 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Lu, Ruinan |e verfasserin |4 aut | |
245 | 1 | 0 | |a Plasma Levels of Big Endothelin-1 Are Associated with Renal Insufficiency and In-Hospital Mortality of Immune Thrombotic Thrombocytopenic Purpura |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 22.03.2022 | ||
500 | |a Date Revised 02.03.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Thieme. All rights reserved. | ||
520 | |a Immune thrombotic thrombocytopenic purpura (iTTP) is caused by severe deficiency of plasma ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) activity. Despite advances in early diagnosis and management, the mortality rate of acute iTTP remains high in a large part of world where access to some of the most novel therapies is limited. To determine the role of plasma big endothelin-1 (bigET-1) or its bioactive product ET-1 as a biomarker and/or a pathogenic factor in acute iTTP, plasma levels of bigET-1 were determined using an immunoassay in patients with iTTP on admission and during remission, as well as in healthy controls; moreover, the biological effect of ET-1 in thrombus formation was determined by a microfluidic assay. We show that plasma levels of bigET-1 were dramatically increased in patients with acute iTTP on admission, which was significantly decreased during clinical response/remission; elevated admission levels of plasma bigET-1 were associated with low estimated glomerular filtration rate, the need for intensive care unit admission or intubation, and in-hospital mortality. Moreover, an addition of a bioactive product ET-1 to cultured endothelial cells in a microfluidic channel significantly accelerated the rate of thrombus formation under arterial flow. Our results demonstrate for the first time a potential role of measuring plasma bigET-1 in patients with acute iTTP in assessing the disease severity and risk of in-hospital mortality, which may help stratify patients for a more aggressive monitoring and therapeutic strategy; also, the bioactive ET-1, derived from bigET-1, may result in acute renal injury in TTP patient, likely through its vasoconstriction and prothrombotic properties | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a Biomarkers |2 NLM | |
650 | 7 | |a Endothelin-1 |2 NLM | |
650 | 7 | |a ADAMTS13 Protein |2 NLM | |
650 | 7 | |a EC 3.4.24.87 |2 NLM | |
650 | 7 | |a ADAMTS13 protein, human |2 NLM | |
650 | 7 | |a EC 3.4.24.87 |2 NLM | |
700 | 1 | |a Zheng, X Long |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Thrombosis and haemostasis |d 1979 |g 122(2022), 3 vom: 25. März, Seite 344-352 |w (DE-627)NLM000103896 |x 2567-689X |7 nnns |
773 | 1 | 8 | |g volume:122 |g year:2022 |g number:3 |g day:25 |g month:03 |g pages:344-352 |
856 | 4 | 0 | |u http://dx.doi.org/10.1055/a-1508-8347 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 122 |j 2022 |e 3 |b 25 |c 03 |h 344-352 |